Bristol‑Myers Squibb and partner SystImmune announced that the Phase III trial of izalontamab brengitecan (Iza‑Bren) met its primary endpoint of progression‑free survival and its secondary endpoint of overall response rate in patients with previously‑treated, unresectable, locally advanced or metastatic triple‑negative breast cancer.
The trial was conducted in China, and BMS holds ex‑China rights after paying SystImmune $800 million upfront in 2023. The positive interim data support BMS’s strategy to expand its oncology pipeline beyond core assets such as Opdivo and Breyanzi, and to offset patent cliffs on legacy products.
BMS will present the full data at the ASCO 2026 Annual Meeting (May 29–June 2) and plans to submit a New Drug Application later in 2026, pending confirmatory Phase III results. The company also recently secured a partnership with Janux Therapeutics and continues to pursue acquisitions to strengthen its oncology portfolio.
The success of Iza‑Bren, an EGFR×HER3 bispecific antibody‑drug conjugate, validates BMS’s investment in ADC technology and positions the company to address an unmet need in triple‑negative breast cancer, a field with limited treatment options. The milestone strengthens BMS’s growth prospects as it navigates patent expirations on its flagship products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.